TNFRSF10B and cancer: For TRAIL has no cytotoxicity in many normal cell types except for human liver cells [30], other agonistic reagents against the pro-apoptotic molecules DR4 or DR5, such as anti-DR5 mAbs, became an attractive anti-cancer strategy because of their potential for inducing tumor-specific cell death.